To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Inclusion Criteria: * The patient or his/her legal representative has signed a written informed consent form and dated it prior to any specific research procedure. * Aged 18 years or older. * Locally advanced or metastatic non-small cell lung cancer with NRG1 fusion detected by DNA or RNA-based next-generation sequencing (NGS) technology in tumor tissue specimens or liquid specimens. * The patient has received platinum-based doublet chemotherapy previously. * ECOG performance status score is 0\~2. * The patient has sufficient bone marrow and organ functionality, which can be proved by complete blood cell count, blood biochemistry and urine biochemistry tests at baseline. * The patient has measurable lesion(s). * The female patient of childbearing age must adopt appropriate contraceptive measures and are not allowed to breastfeed a child. * The male patient must voluntarily use contraceptives. Exclusion Criteria: * The patient has shown any severe or uncontrollable systemic disease sign that the investigators believe may significantly change the risk/benefit balance of the patient, including uncontrollable hypertension, high active bleeding tendency, active infection or significant damage of bone marrow or other functions. * The patient has previously been treated with EGFR-TKI or any monoclonal antibody that acts on HER2/3. * The patient has been found with symptomatic metastatic tumor of central nervous system (CNS). * The patient has a history of interstitial pneumonia o…